Overview
- The Centers for Medicare & Medicaid Services finalized a rule this week that bars federal Medicaid payments for puberty blockers, cross-sex hormones and gender-related surgeries for children under 18 in Medicaid and under 19 in CHIP.
- The rule preserves federal coverage for psychotherapy and grants narrow exceptions for intersex care and complications from prior procedures while allowing states to use their own funds if they choose to keep paying for treatments.
- Children already on hormone therapy will receive up to six months of federally funded coverage after the rule takes effect to permit a clinician-guided tapering off of medication.
- CMS said its decision rests on an HHS review and international reports such as the UK Cass Review, projected roughly $235 million in combined Medicaid and CHIP savings over ten years, and faces immediate political criticism and expected legal challenges from states, medical groups and LGBTQ+ advocates.
- This action follows a broader White House push to restrict transgender-related policies and will shift care access and costs onto states, families and private insurers while prompting lawsuits and state-level policy responses.